Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIGHT-205 first-line FGFR3-altered urothelial carcinoma study
jRCT2080225018Phase 2Completed
- Sponsor
- Incyte
- Start
- Jan 2020
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
01
Overview
Phase 2, randomised, open-label trial in transitional cell carcinoma (TCC) comparing Pemigatinib plus pembrolizumab, Pemigatinib monotherapy and Standard of care gemcitabine plus carboplatin (3 arms). Started Jan 2020; status: completed.
02
Drugs
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on jRCT2080225018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225018.